{"groups":[{"description":"Patients with non-squamous NSCLC regardless of genomic alteration status (newly diagnosed or progressing on therapy)","id":"FG000","title":"A - NSCLC All Comers Regardless of Genomic Alteration Status"},{"description":"Patients with non-squamous NSCLC progressing on erlotinib, gefitinib, or afatinib","id":"FG001","title":"B - Progressing on EGFR Targeted Therapies"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"121"},{"groupId":"FG001","numSubjects":"19"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"121"},{"groupId":"FG001","numSubjects":"19"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}